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forThisincreasing
time without fever and the relief of feverarticle is a U.S. government work, and is not subject to copyright in the United States.
associated discomfort?
Design

Randomized, blinded, 3-arm trial.

Setting

Primary care settings in Bristol, England.

Participants A total of 156 children, ages 6 months to 6
years with axillary temperatures of at least 37.8° C and up to
41.0° C.

Advice on physical measures to reduce temperature and the provision of, and advice to give, acetaminophen plus ibuprofen, acetaminophen alone, or ibuprofen
alone.

Intervention

Primary outcomes were the time without fever
(⬍37.2° C) in the first 4 hours after the first dose was given
and the proportion of children reported as being normal on
the discomfort scale at 48 hours. Secondary outcomes were
time to first occurrence of normal temperature (fever clearance), time without fever over 24 hours, fever-associated
symptoms, and adverse effects.

Outcomes

On an intention to treat basis, acetaminophen
plus ibuprofen were superior to acetaminophen for less time with
Review
of 55=>
fever in the first four hours (adjusted
difference
minutes, 95%
confidence interval 33 to 77; P ⬍ .001) and may have been as
good as ibuprofen (16 minutes, ⫺7 to 39; P ⫽ 0.2). For less time
with fever over 24 hours, acetaminophen plus ibuprofen were
superior to acetaminophen (4.4 hours, 2.4 to 6.3; P ⬍ .001) and
to ibuprofen (2.5 hours, 0.6 to 4.4; P ⫽ .008). Combined therapy
cleared fever 23 minutes (2 to 45; P ⫽ .025) faster than acetaminophen alone but no faster than ibuprofen alone (⫺3 minutes, 18 to ⫺24; P ⫽ .8). No benefit was found for discomfort
or other symptoms, although power was low for these outcomes.
Adverse effects did not differ between groups.
Main Results

Conclusions Parents, nurses, pharmacists, and doctors
wanting to use medicines to supplement physical measures to
maximize the time that children spend without fever should
use ibuprofen first and consider the relative benefits and risks
of using acetaminophen plus ibuprofen over 24 hours.
Commentary Fever is common in children and causes par-

ents to worry. Most febrile children have self-limiting infections and will get better without treatment. But young children who are febrile are usually uncomfortable and miserable.
It is standard practice for doctors to recommend, and parents
to administer, antipyretic treatment. The 2 most widely used
drugs are acetaminophen and ibuprofen. Recently it has become increasingly common for doctors to recommend a combination of both drugs, so this primary care study randomizing feverish young children to either drug alone or a
combination of the 2 drugs is timely. The authors report 2
primary outcomes: time without fever in first 4 hours and
fever-associated discomfort after 48 hours. The first could be
argued to represent a proxy of parental concern, but it is
fever-associated discomfort that is the key outcome. And for
this outcome, the study is underpowered. One hundred fifty462

six children were recruited and randomized from 1038
potentially eligible participants. Despite this, their results
suggest no additional improvement in fever-associated discomfort or activity levels in the combined medication group at
24 hours, 48 hours, and 5 days. Their data confirm that
ibuprofen is faster acting and has a longer duration than
acetaminophen but that a combination of drugs has little
advantage. Of some concern is their report of 31 children in
the combined group receiving an overdose of medication even
in clinical trial conditions. A larger trial is required to confirm
their findings, but for now, I am not persuaded that prescribing a combination of acetaminophen and ibuprofen for the
treatment of feverish young children has any advantage over
use of either drug alone.
Anthony Harnden, MB ChB, FRCGP, FRCPCH
Oxford University
Oxford, United Kingdom

Nicotine nasal spray neither effective nor
well-tolerated by adolescent smokers
Rubinstein ML, Benowitz NL, Auerback GM, Moscicki A.
A randomized trial of nicotine nasal spray in adolescent
smokers. Pediatrics 2008;122:e595-e600.
Among adolescent smokers who wanted to quit
smoking, is nicotine nasal spray effective at increasing cessation rates?

Question

Design

Randomized, open-label, 12-week trial.

Setting

Five San Francisco Bay Area high schools.

Participants Forty adolescents, ages 15 to 18 years of age,
who smoked ⱖ5 cigarettes daily for at least 6 months.
Intervention Participants were assigned to receive either
weekly counseling alone (control) for 8 weeks or 6 weeks of
nicotine nasal spray along with 8 weeks of counseling.
Outcomes Self-reported smoking abstinence, as verified by

both expired-air carbon monoxide and salivary cotinine levels.
Main Results There was no difference in cessation rates, the

number of cigarettes smoked per day, or cotinine levels at 12
weeks. Fifty-seven percent of participants stopped using their
spray after only 1 week. The most commonly reported adverse
effect was nasal irritation and burning (34.8%), followed by
complaints about the taste and smell (13%).
The unpleasant adverse effects, poor adherence, and consequent lack of efficacy observed in this pilot
study do not support the use of nicotine nasal spray as an
adjunct to counseling for adolescent smokers who wish to
quit.

Conclusions

Commentary This is an important and well-designed first
study of the effect of nicotine nasal spray (NNS) on adolescent smoking cessation that supports current evidence-based
guidelines that nicotine replacement therapy is neither effective nor recommended for adolescents.1 NNS theoretically
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could succeed for adolescents where other forms of nicotine
replacement failed. Consistent with adolescent tobacco use
patterns, potential benefits of NNS over other forms of nicotine replacement include the following: (1) NNS can be used
intermittently, (2) in response to environmental influences,
such as smoking to relieve stress, NNS has a relatively fast
delivery of nicotine with reinforcing effects, and (3) compared
with other forms of nicotine replacement, NNS allows greater
self-control and ownership of the intervention, which adolescents prefer. Admirably, this study uses a validated nicotine dependence questionnaire for adolescents, a withdrawal symptom scale, biochemical validation of self-report,
and an intention-to-treat analysis. Two noteworthy design
limitations exist: First, this is an open-label trial without a
placebo group. Second, although originally designed to be an
effectiveness study, failure to meet sample size requirements
forced the authors to truncate the study for feasibility. These
limitations are relatively minor, however, because this study
convincingly shows that NNS is not tolerated by adolescents.
Although the delivery system holds promise for adolescent
smokers, the negative side effects of the spray, in particular
burning associated with use, led to such poor adherence that
discussion of efficacy is moot. If future NNS preparations are
better tolerated, this study deserves replication with adequate
power to reexamine the issue of effectiveness for adolescents.

Main Results The changes in glycated hemoglobin levels in

the 2 study groups varied markedly according to age group
(P ⫽ .003), with a significant difference among patients 25
years of age or older that favored the continuous-monitoring
group (mean difference in change, ⫺0.53%; 95% confidence
interval [CI], ⫺0.71 to ⫺0.35; P ⬍ .001). The betweengroup difference was not significant among those who were
15 to 24 years of age (mean difference, 0.08; 95% CI, ⫺0.17
to 0.33; P ⫽ 0.52) or among those who were 8 to 14 years of
age (mean difference, ⫺0.13; 95% CI, ⫺0.38 to 0.11; P ⫽
.29). Secondary glycated hemoglobin outcomes were better in
the continuous-monitoring group than in the control group
among the oldest and youngest patients but not among those
who were 15 to 24 years of age. The use of continuous glucose
monitoring averaged 6.0 or more days per week for 83% of
patients 25 years of age or older, 30% of those 15 to 24 years
of age, and 50% of those 8 to 14 years of age. The rate of
severe hypoglycemia was low and did not differ between the
2 study groups; however, the trial was not powered to detect
such a difference.
Conclusions Continuous glucose monitoring can be associ-

ated with improved glycemic control in adults with type 1
diabetes, but was not effective in children and adolescents.
This is the largest, prospective, individually
randomized unblinded controlled trial of continuous glucose
monitoring (CGM). Use of CGM was associated with significantly improved glycemic control in adults with type 1
diabetes, but not children or adolescents. Between-group
A1C levels fell by a mean of 0.53% in adults. Nonsignificant
benefit of CGM was observed in subjects who were 8 to 14
years of age, and no benefit was observed among subjects who
were 15 to 24 years of age. Why didn’t children and adolescents benefit? The reasons might be related to adherence and
to the study’s method for randomization. Use of CGM is a
tool for directing behavior on the basis of glucose levels.
Adherence to a behavioral intervention is necessary for the
intervention to be successful.1 Adherence alone might account for the ranking of results between adults with the
greatest compliance (80%) and greatest benefit, compared
with children with the second-best compliance (50%) and
second best results, and adolescents with the least compliance (33%) least benefit. The study used individual randomization, which is appropriate for a blinded trial, but in
an unblinded trial of a behavioral intervention, cluster
randomization of study sites is often used to prevent contamination of control subjects from knowledge of the intervention.2 If control subjects learn about benefits of using
CGM at the investigator’s office, then they might monitor
their glucose more frequently and artifactually improve
their control. This behavior could improve the A1C outcome for controls and wash out the between-group benefit
of the CGM intervention. Indeed, in this study the children and adolescent control subjects both had at least a

Commentary

William P. Adelman, MD
Uniformed Services University of the Health Sciences
Bethesda, Maryland
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Continuous glucose monitoring study does not
demonstrate benefit in children and adolescents
The Juvenile Diabetes Research Foundation Continuous
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Among patients with type 1 diabetes mellitus,
does the use of continuous glucose monitoring result in improved glycemic control?

Question

Design

Randomized, controlled trial.

Setting

Multiple centers in the United States.

Participants A total of 322 adults and children who were
already receiving intensive therapy for type 1 diabetes.

Continuous glucose monitoring or a control
group performing home monitoring with a blood glucose
meter.

Intervention

Outcomes

Change in the glycated hemoglobin level at 26

weeks.
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